BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20181447)

  • 1. Causal mechanism for atherosclerosis or coronary heart disease in women: a constellation of components.
    Agrinier N; Cournot M; Ruidavets JB; Ahluwalia N; Ferrières J
    Maturitas; 2010 Apr; 65(4):404-5. PubMed ID: 20181447
    [No Abstract]   [Full Text] [Related]  

  • 2. Should all patients with systemic lupus erythematosus receive cardioprotection with statins?
    Toloza S; Urowitz MB; Gladman DD
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):536-7. PubMed ID: 17700557
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive cholesterol lowering: no longer a myth.
    Bitzur R; Harats D
    Isr Med Assoc J; 2005 Dec; 7(12):816-7. PubMed ID: 16382708
    [No Abstract]   [Full Text] [Related]  

  • 4. Viewpoint: Terje R. Pedersen, MD, PhD. Interview by Robert Short.
    Pedersen TR
    Circulation; 2007 Mar; 115(12):f51-2. PubMed ID: 17393574
    [No Abstract]   [Full Text] [Related]  

  • 5. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
    Davidson MH
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
    [No Abstract]   [Full Text] [Related]  

  • 6. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins, cholesterol, and the prevention of coronary heart disease.
    Freeman MW
    FASEB J; 2006 Feb; 20(2):200-1. PubMed ID: 16449790
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Daniels SR; Gidding SS; de Ferranti SD;
    J Clin Lipidol; 2011 Jun; 5(3 Suppl):S30-7. PubMed ID: 21600527
    [No Abstract]   [Full Text] [Related]  

  • 9. Towards consistency between guidelines and policy: lipid management--2005.
    Tonkin AM
    Heart Lung Circ; 2005 Dec; 14(4):237-8. PubMed ID: 16360991
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
    Idzior-Waluś B
    Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins. Cholesterol lowering and beyond.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):1-2. PubMed ID: 16675916
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical inquiries. What is the target for low-density lipoprotein cholesterol in patients with heart disease?
    Stevermer JJ; Meadows SE
    J Fam Pract; 2002 Oct; 51(10):893. PubMed ID: 12401164
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-density lipoprotein cholesterol reduction: the end is more important than the means.
    LaRosa JC
    Am J Cardiol; 2007 Jul; 100(2):240-2. PubMed ID: 17631077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention and treatment of coronary heart disease. The importance of cholesterol synthesis enzyme inhibition].
    Kostner K
    Pharm Unserer Zeit; 2003; 32(6):480-7. PubMed ID: 14639829
    [No Abstract]   [Full Text] [Related]  

  • 15. Don't trust an LDL over 70?
    Aronow WS
    Geriatrics; 2004 May; 59(5):12-3. PubMed ID: 15152729
    [No Abstract]   [Full Text] [Related]  

  • 16. Statins, low cholesterol, and hemorrhagic stroke: an uncertain triangle.
    Jacobs BS; Greenberg SM
    Neurology; 2008 Jun; 70(24 Pt 2):2355-6. PubMed ID: 18541869
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefits of atorvastatin in cholesterol lowering.
    Farmer JA
    Curr Atheroscler Rep; 2003 Mar; 5(2):94-5. PubMed ID: 12573192
    [No Abstract]   [Full Text] [Related]  

  • 18. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
    J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight of the evidence in statin clinical trials: comparing the results.
    Clearfield MB
    J Am Osteopath Assoc; 2003 Jul; 103(7 Suppl 3):S4-11. PubMed ID: 12884938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.